Repros Therapeutics Inc. (NASDAQ:RPRX) Issues Quarterly Earnings Results
Repros Therapeutics Inc. (NASDAQ:RPRX) released its quarterly earnings results on Monday. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.14, Bloomberg Earnings reports. Repros Therapeutics had a negative return on equity of 276.50% and a negative net margin of 49,564.86%.
Repros Therapeutics (RPRX) traded down 5.71% on Monday, hitting $0.33. The stock had a trading volume of 49,784 shares. The company’s 50 day moving average price is $0.41 and its 200-day moving average price is $0.83. The company’s market cap is $8.82 million. Repros Therapeutics has a 12-month low of $0.29 and a 12-month high of $2.48.
Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.
TRADEMARK VIOLATION WARNING: “Repros Therapeutics Inc. (NASDAQ:RPRX) Issues Quarterly Earnings Results” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/14/repros-therapeutics-inc-nasdaqrprx-issues-quarterly-earnings-results.html.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.